Loading...

Royalty Pharma plc

RPRXNASDAQ
Healthcare
Biotechnology
$36.67
$0.08(0.22%)

Fundamental Analysis of Royalty Pharma plc (RPRX)

Comprehensive financial metrics and ratios analysis
EPS (TTM)
$2.45
P/E Ratio
14.97
ROE
0.16%
Net Margin
0.48%

Key Financial Metrices

Valuation Metrics

4 metrics
Market CapTotal market value of outstanding shares
$20.62B
Shares OutstandingTotal number of shares issued
$562.29M
Book Value/ShareNet worth per share
$22.58
Revenue/ShareAnnual revenue per share
$5.22

Profitability Metrics

6 metrics
EPS (TTM)Earnings per share trailing twelve months
$2.45
Net MarginNet income as percentage of revenue
48.24%
Operating MarginOperating income as percentage of revenue
83.95%
ROEReturn on shareholders' equity
16.19%
ROAReturn on total assets
6.20%
ROCEReturn on capital employed
11.57%

Cash Flow Metrics

3 metrics
Free Cash Flow/ShareCash generated per share after capex
$6.23
Cash/ShareCash and equivalents per share
$4.19
FCF YieldFree cash flow as percentage of market cap
13.12%

Dividend Metrics

2 metrics
Dividend/ShareAnnual dividend payment per share
$0.86
Dividend YieldAnnual dividend as percentage of stock price
2.35%
Financial Ratios Analysis data is not available for RPRXFinancial Ratios Analysis details for RPRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Sector Benchmarking data is not available for RPRXSector Benchmarking details for RPRX are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Royalty Pharma plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Royalty Pharma plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Royalty Pharma plc's unique business strengths and challenges.

Key Financial Metrics for Royalty Pharma plc

For Royalty Pharma plc, essential financial indicators include EPS 2.45, PE 14.97, and ROE 0.16. These key ratios reveal insights into Royalty Pharma plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare Royalty Pharma plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Royalty Pharma plc

Metrics like Net Margin 48.24% and ROA 6.20% shed light on how well Royalty Pharma plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Royalty Pharma plc can sustain its operations and continue growing in the future.

Valuation and Market Position of Royalty Pharma plc

Using ratios such as P/B Ratio 2.37 and PEG Ratio 0.62, investors can assess whether Royalty Pharma plc is appropriately valued based on its financials and growth potential. These figures, combined with Royalty Pharma plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Royalty Pharma plc

Financial health indicators, such as Debt/Equity Ratio 1.14 and Cash Flow $6.23, provide a snapshot of Royalty Pharma plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Royalty Pharma plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Royalty Pharma plc

Investing in Royalty Pharma plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Royalty Pharma plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;